abiraterone,olaparib
astrazeneca,merck
['abira', 'prostate', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'olaparib', 'propel', 'abiraterone']
propel met its primary endpoint demonstrating a statistically significant rpfs benefit in the itt population of patients with 1l mcrpc treated with abiraterone + olaparib versus abiraterone + placebo. not significant in os. #gu23 #prostatecancer 
Jefe de Servicio de Oncología Médica. Hospital Universitario Lucus Augusti, HULA. Grupo de Investigación Oncológica Traslacional, GIOT HULA. Cuenta personal